Journal
BRITISH JOURNAL OF CANCER
Volume 108, Issue 5, Pages 997-1003Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2013.24
Keywords
pancreatic cancer; inflammation; therapy
Categories
Funding
- Wellcome Trust
- Cancer Research UK
- Cancer Research UK [11650, 12481] Funding Source: researchfish
- Chief Scientist Office [CAF/06/24] Funding Source: researchfish
Ask authors/readers for more resources
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy associated with <5% 5-year survival, in which standard chemotherapeutics have limited benefit. The disease is associated with significant intra-and peritumoral inflammation and failure of protective immunosurveillance. Indeed, inflammatory signals are implicated in both tumour initiation and tumour progression. The major pathways regulating PDAC-associated inflammation are now being explored. Activation of leukocytes, and upregulation of cytokine and chemokine signalling pathways, both have been shown to modulate PDAC progression. Therefore, targeting inflammatory pathways may be of benefit as part of a multi-target approach to PDAC therapy. This review explores the pathways known to modulate inflammation at different stages of tumour development, drawing conclusions on their potential as therapeutic targets in PDAC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available